Parametric Portfolio Associates LLC boosted its stake in shares of Diplomat Pharmacy Inc (NYSE:DPLO) by 50.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 186,992 shares of the company’s stock after acquiring an additional 63,019 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Diplomat Pharmacy were worth $1,139,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in DPLO. First Trust Advisors LP boosted its stake in Diplomat Pharmacy by 154.6% during the first quarter. First Trust Advisors LP now owns 56,438 shares of the company’s stock worth $328,000 after buying an additional 34,274 shares during the period. KBC Group NV purchased a new position in Diplomat Pharmacy during the second quarter worth about $46,000. Aperio Group LLC boosted its stake in Diplomat Pharmacy by 127.0% during the second quarter. Aperio Group LLC now owns 28,304 shares of the company’s stock worth $172,000 after buying an additional 15,834 shares during the period. Stephens Inc. AR boosted its stake in Diplomat Pharmacy by 1,482.3% during the second quarter. Stephens Inc. AR now owns 6,600,015 shares of the company’s stock worth $40,194,000 after buying an additional 6,182,889 shares during the period. Finally, Swiss National Bank boosted its stake in Diplomat Pharmacy by 20.3% during the second quarter. Swiss National Bank now owns 110,800 shares of the company’s stock worth $675,000 after buying an additional 18,700 shares during the period. 84.58% of the stock is owned by institutional investors.
NYSE DPLO opened at $4.66 on Friday. The firm has a 50 day simple moving average of $5.47 and a 200-day simple moving average of $5.43. The company has a debt-to-equity ratio of 1.53, a quick ratio of 0.66 and a current ratio of 0.99. Diplomat Pharmacy Inc has a one year low of $4.17 and a one year high of $21.48. The firm has a market cap of $353.37 million, a price-to-earnings ratio of 23.30 and a beta of 0.99.
Several brokerages have weighed in on DPLO. Barclays set a $7.00 target price on shares of Diplomat Pharmacy and gave the stock a “buy” rating in a research note on Friday, August 9th. Deutsche Bank began coverage on shares of Diplomat Pharmacy in a research note on Thursday, September 12th. They set a “sell” rating and a $4.00 target price for the company. Wells Fargo & Co increased their target price on shares of Diplomat Pharmacy from $5.00 to $5.50 and gave the stock a “market perform” rating in a research note on Tuesday, August 13th. ValuEngine lowered shares of Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 2nd. Finally, Zacks Investment Research lowered shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Wednesday, August 14th. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $9.43.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Featured Article: What is the accumulation/distribution indicator?
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.